These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 22335400)

  • 1. Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists.
    Janero DR
    Expert Opin Emerg Drugs; 2012 Mar; 17(1):17-29. PubMed ID: 22335400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk.
    Janero DR; Lindsley L; Vemuri VK; Makriyannis A
    Expert Opin Drug Discov; 2011 Oct; 6(10):995-1025. PubMed ID: 22646861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis.
    Janero DR; Makriyannis A
    Expert Opin Emerg Drugs; 2009 Mar; 14(1):43-65. PubMed ID: 19249987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.
    Vemuri VK; Janero DR; Makriyannis A
    Physiol Behav; 2008 Mar; 93(4-5):671-86. PubMed ID: 18155257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
    Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological comparison of traditional and non-traditional cannabinoid receptor 1 blockers in rodent models in vivo.
    Varga B; Kassai F; Szabó G; Kovács P; Fischer J; Gyertyán I
    Pharmacol Biochem Behav; 2017 Aug; 159():24-35. PubMed ID: 28666894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development.
    Nguyen T; Thomas BF; Zhang Y
    Curr Top Med Chem; 2019; 19(16):1418-1435. PubMed ID: 31284863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders.
    Beardsley PM; Thomas BF; McMahon LR
    Int Rev Psychiatry; 2009 Apr; 21(2):134-42. PubMed ID: 19367507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective therapeutic agents for obesity: molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists.
    Sharma MK; Murumkar PR; Kanhed AM; Giridhar R; Yadav MR
    Eur J Med Chem; 2014 May; 79():298-339. PubMed ID: 24747288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning?
    Bermudez-Silva FJ; Viveros MP; McPartland JM; Rodriguez de Fonseca F
    Pharmacol Biochem Behav; 2010 Jun; 95(4):375-82. PubMed ID: 20347862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge.
    Soler-Cedeno O; Xi ZX
    Cells; 2022 Oct; 11(20):. PubMed ID: 36291128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.
    Galaj E; Xi ZX
    CNS Drugs; 2019 Oct; 33(10):1001-1030. PubMed ID: 31549358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders.
    Beardsley PM; Thomas BF
    Behav Pharmacol; 2005 Sep; 16(5-6):275-96. PubMed ID: 16148435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe.
    Laprairie RB; Kulkarni AR; Kulkarni PM; Hurst DP; Lynch D; Reggio PH; Janero DR; Pertwee RG; Stevenson LA; Kelly ME; Denovan-Wright EM; Thakur GA
    ACS Chem Neurosci; 2016 Jun; 7(6):776-98. PubMed ID: 27046127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Energy balance regulation by endocannabinoids at central and peripheral levels.
    Quarta C; Mazza R; Obici S; Pasquali R; Pagotto U
    Trends Mol Med; 2011 Sep; 17(9):518-26. PubMed ID: 21816675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Synthesis of Cannabinoid 1 Receptor (CB1R) Allosteric Modulators: Drug Discovery Applications.
    Kulkarni AR; Garai S; Janero DR; Thakur GA
    Methods Enzymol; 2017; 593():281-315. PubMed ID: 28750808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity.
    Meye FJ; Trezza V; Vanderschuren LJ; Ramakers GM; Adan RA
    Mol Psychiatry; 2013 Dec; 18(12):1294-301. PubMed ID: 23070073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allosteric Modulation of Cannabinoid Receptor 1-Current Challenges and Future Opportunities.
    Hryhorowicz S; Kaczmarek-Ryś M; Andrzejewska A; Staszak K; Hryhorowicz M; Korcz A; Słomski R
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity.
    Tam J; Vemuri VK; Liu J; Bátkai S; Mukhopadhyay B; Godlewski G; Osei-Hyiaman D; Ohnuma S; Ambudkar SV; Pickel J; Makriyannis A; Kunos G
    J Clin Invest; 2010 Aug; 120(8):2953-66. PubMed ID: 20664173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents.
    Sharma MK; Murumkar PR; Barmade MA; Giridhar R; Yadav MR
    Expert Opin Ther Pat; 2015; 25(10):1093-116. PubMed ID: 26161824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.